Loading...
01/10 16:47
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents a mixed outlook. Financial performance showed improvements in ACV and renewal rates, but revenue remained flat, and a net loss was reported. The Q&A highlighted innovation in AI and potential growth in IP, but management's unclear responses on long-term potential and AI's competitive edge raise concerns. Despite raised guidance, the flat revenue and net loss, coupled with market uncertainties, suggest a neutral sentiment. Given the mid-sized market cap, the stock is likely to see minor fluctuations, leading to a neutral prediction of -2% to 2%.
Annual Contract Value (ACV) Improved to 1.6%, a 30 basis point sequential improvement, driven by 2% ACV growth across Academia & Government and Life Sciences & Health.
Renewal Rate Increased to 93%, up 100 basis points year-over-year, reflecting strong customer retention.
Free Cash Flow Generated $115 million year-to-date, supporting share repurchases and debt paydown.
Revenue (Q3 2025) $623 million, essentially flat compared to the prior year.
Net Loss (Q3 2025) $28 million, an improvement over the prior year due to higher foreign exchange gains and the absence of a noncash impairment charge recorded last year.
Adjusted Diluted EPS (Q3 2025) Flat sequentially at $0.18, with changes attributed to the divestiture of ScholarONE.
Operating Cash Flow (Q3 2025) $181 million, with changes driven by adjusted EBITDA and working capital.
Recurring Organic Revenue Growth (First 9 months of 2025) Improved to 0.6% compared to 0.1% last year.
Organic Revenue Mix Increased to 88%, up from 80% in 2024.
Year-to-Date Revenue (2025) $1.84 billion, a decline of more than $50 million compared to the prior year, driven by disposals and divestitures.
Year-to-Date Free Cash Flow (2025) $276 million, with changes driven by adjusted EBITDA impact and lower capital spending.
AI-powered solutions: Clarivate introduced 12 new products and AI-powered capabilities across its segments, including Web of Science Research Intelligence, AI agent, trademark opposition assistant, RiskMark, and regulatory functionality within Cortellis.
Life Sciences & Health: Launched DRG Commercial Analytics 360 for medtech and AI-powered regulatory assistant in Cortellis Regulatory Intelligence, enhancing decision-making and efficiency.
Intellectual Property: Introduced AI-powered product taxonomy in IPfolio and Derwent patent monitor for better patent management and risk mitigation.
Global Reach: Secured contracts with major institutions like the British Library, Canadian Research Knowledge Network, CAPES in Brazil, and University of Melbourne.
A&G Segment: Transitioned from transactional sales to subscription-based revenue, achieving a 93% subscription mix compared to 81% last year.
Value Creation Plan (VCP): Focused on growth, innovation, and operational efficiency, resulting in improved renewal rates (93%) and organic revenue mix (88%).
Cost Efficiency: Achieved cost savings through disposals and streamlined operations, reducing capital spending by $30 million.
Strategic Alternatives: Actively reviewing strategic alternatives with updates expected in Q4 2025.
Business Model Optimization: Exited A&G transactional book sales and life sciences real-world data reselling market to focus on core areas.
Market Conditions: The company faces challenges due to constraints on higher education research funding, particularly in the U.S., which could impact renewals and revenue from academic institutions.
Regulatory Hurdles: The company is navigating global regulatory requirements, which may pose challenges in managing compliance efficiently, despite the introduction of AI-powered regulatory tools.
Economic Uncertainties: Foreign exchange fluctuations have impacted financial results, with a weaker U.S. dollar providing a tailwind but also introducing unpredictability in revenue and profit margins.
Strategic Execution Risks: The company is undergoing significant transitions, including exiting transactional book sales and the life sciences real-world data reselling market, which could disrupt operations and revenue streams during the transition period.
Competitive Pressures: The company is investing heavily in AI and product innovation to maintain its competitive edge, but there is a risk that competitors may outpace these efforts or that the investments may not yield the expected returns.
Supply Chain Disruptions: No explicit mention of supply chain disruptions was noted in the transcript.
Annual Contract Value (ACV): Expected continued acceleration in ACV growth in Q4 2025, with organic ACV growth already at 1.6% year-to-date.
Recurring Organic Revenue Growth: Anticipated to remain in the upper half of the guidance range for 2025, with organic recurring revenue mix at 88% year-to-date.
Revenue Guidance: Raised to $2.44 billion at the midpoint of the new range for 2025, reflecting better-than-expected organic performance and slower-than-anticipated attrition in business disposals.
Adjusted EBITDA: Expected to reach the high end of the guidance range for 2025, with a profit margin of approximately 41%.
Free Cash Flow: Projected to be near the midpoint of the guidance range for 2025, with a conversion rate of approximately 34% of adjusted EBITDA.
AI and Product Innovation: Plans to accelerate AI innovation at scale, embedding AI across customer workflows and launching new AI-native solutions in 2026 to drive organic ACV and recurring revenue growth.
Operational Efficiency and Margin Expansion: Aiming to achieve through organization-wide AI adoption and cost efficiencies.
Strategic Disposals: Expected to lower revenue by approximately $90 million in 2025, with most of the remaining impact occurring in 2026.
Capital Allocation: Flexibility between share repurchases and deleveraging in Q4 2025.
2026 Focus: Continued execution of the value creation plan, rapid deployment of AI solutions, and operational excellence to drive innovation and shareholder value.
Share Repurchases: Clarivate has executed $115 million of opportunistic share repurchases year-to-date. Additionally, during the third quarter, the company repurchased another 11.7 million shares, bringing the year-to-date buybacks to $150 million. This balanced capital deployment has allowed Clarivate to retire nearly $35 million or about 5% of its outstanding shares.
The earnings call presents a mixed outlook. Financial performance showed improvements in ACV and renewal rates, but revenue remained flat, and a net loss was reported. The Q&A highlighted innovation in AI and potential growth in IP, but management's unclear responses on long-term potential and AI's competitive edge raise concerns. Despite raised guidance, the flat revenue and net loss, coupled with market uncertainties, suggest a neutral sentiment. Given the mid-sized market cap, the stock is likely to see minor fluctuations, leading to a neutral prediction of -2% to 2%.
The earnings call highlights strong financial metrics, such as increased EBITDA margin, high renewal rates, and significant share repurchase, which are positive indicators. The Q&A section reveals management's confidence in capitalizing on AI opportunities and maintaining strong renewal rates. Although there are some uncertainties like the US patent fee changes, the overall sentiment is positive due to strategic partnerships, improved recurring revenue, and a subscription-centric model. Given the mid-cap market cap, the stock price is likely to react positively, with an expected increase of 2% to 8%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
